GlassScriptPhysician profile
Dawn M Grimm
NPI 1588157465
$2,981.36
in general payments reported to CMS, 2019-2025
32 companies · $1,058 in 2025
The $1,058 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $67.12 · 2023: $801 · 2024: $1,055 · 2025: $1,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,604 · Education: $712 · Long Term Medical Supply Or Device Loan: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,603.96 |
| Education | $712.08 |
| Long Term Medical Supply Or Device Loan | $598.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $751.61 | 2023-2025 | |
| Incyte Corporation | $348.80 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Gilead Sciences, INC. | $194.64 | 2024-2025 | Trodelvy |
| Pfizer INC. | $152.24 | 2023-2025 | |
| Lilly USA, LLC | $144.98 | 2022-2024 | Verzenio, Jaypirca |
| Astrazeneca Pharmaceuticals LP | $125.69 | 2023-2025 | Calquence |
| Astellas Pharma US INC | $114.70 | 2024 | Padcev |
| E.R. Squibb & Sons, L.L.C. | $104.58 | 2024 | |
| Mirati Therapeutics, INC. | $92.67 | 2024 | Krazati |
| Genentech USA, INC. | $81.77 | 2022-2025 | Tecentriq, Lunsumio |
| Abbvie INC. | $74.12 | 2024-2025 | |
| Seagen INC. | $74.00 | 2025 | |
| Eisai INC. | $72.02 | 2023-2024 | |
| Tersera Therapeutics LLC | $66.32 | 2023-2025 | Xermelo, Zoladex |
| Janssen Biotech, INC. | $65.14 | 2023 | Darzalex, Tecvayli, Imbruvica |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $59.91 | 2022-2023 | Keytruda, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $52.81 | 2022-2023 | |
| Amgen INC. | $49.22 | 2023 | Blincyto, Kyprolis, Lumakras |
| Emd Serono, INC. | $42.34 | 2025 | |
| Jazz Pharmaceuticals INC. | $39.11 | 2024 | |
| Sobi, INC | $35.97 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $31.36 | 2023 | Libtayo |
| Daiichi Sankyo INC. | $27.95 | 2024 | Enhertu |
| Alexion Pharmaceuticals, INC. | $25.13 | 2023 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $24.62 | 2024 | Cosela |
| Servier Pharmaceuticals LLC | $22.75 | 2024 | |
| Puma Biotechnology, INC. | $21.02 | 2023 | |
| Genzyme Corporation | $20.95 | 2024 | |
| Apellis Pharmaceuticals, INC. | $18.14 | 2024 | Empaveli |
| Pharmacyclics LLC, An Abbvie Company | $16.40 | 2023 | Imbruvica |
| Geron Corporation | $15.90 | 2025 | Rytelo |
| Ipsen Biopharmaceuticals, INC | $14.50 | 2023 | Tazverik |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Grimm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.